Loading…
Reported covered position: Vice President of Government Affairs
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Expanding Access to Low-Cost Generics Act of 2023
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Expanding Access to Low-Cost Generics Act of 2023
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2026 · third_quarter · Q3
Patent Thickets, Interchangeability of biosimilars, Clinical Trials exemption for biosimilars, "Net Effective Cost" PBM reform, Country of Origin labeling, Abbreviated Drug Labeling, Tariffs, Domestic Manufacturing, DSCSA.
Incentivizing domestic manufacturing of essential medicines.
Source: Senate LDA
Expanding Access to Low-Cost Generics Act of 2023
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114).
Expanding Access to Low-Cost Generics Act of 2023
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Expanding Access to Low-Cost Generics Act of 2023
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Expanding Access to Low-Cost Generics Act of 2023
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Expanding Access to Low-Cost Generics Act of 2023
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Expanding Access to Low-Cost Generics Act of 2023
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Expanding Access to Low-Cost Generics Act of 2023
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Expanding Access to Low-Cost Generics Act of 2023
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
Patent Settlments BLOCKING Act (H.R. 938). Pharmaceutical Supply Chain Medicaid & Medicare
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
Hatch-Waxman Integrity Act of 2019
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
Hatch-Waxman Integrity Act of 2019
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
Hatch-Waxman Integrity Act of 2019
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
Hatch-Waxman Integrity Act of 2019
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
Preserve Access to Affordable Generics and Biosimilars Act
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
Preserve Access to Affordable Generics and Biosimilars Act
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
Preserve Access to Affordable Generics and Biosimilars Act
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
Preserve Access to Affordable Generics and Biosimilars Act
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
A bill for the relief of Jose Alberto Martinez Moreno, Micaela Lopez Martinez, and Adilene Martinez.
Client: LUPIN PHARMACEUTICALS INC · Firm: LUPIN PHARMACEUTICALS INC
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. Patent settlements legislation USMCA - regarding IP standards in USMCA. IPR - regarding PTO authority to administrative review of patents.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues.
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. Patent settlements legislation.
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. Patent settlements legislation.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Reimbursement of generic pharmaceuticals and biosimilars.
Country of Origin labeling.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2026 · second_quarter · Q2
Patent Thickets, Interchangeability of biosimilars, Clinical Trials exemption for biosimilars, "Net Effective Cost" PBM reform, Country of Origin labeling, Abbreviated Drug Labeling, Tariffs, Domestic Manufacturing, DSCSA.
Incentivizing domestic manufacturing of essential medicines.
Reimbursement of generic pharmaceuticals and biosimilars.
Country of Origin labeling.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2026 · first_quarter · Q1
Country of Origin labeling.
Incentivizing domestic manufacturing of essential medicines.
Reimbursement of generic pharmaceuticals and biosimilars.
Patent Thickets, Interchangeability of biosimilars, Clinical Trials exemption for biosimilars, "Net Effective Cost" PBM reform, Country of Origin labeling, Abbreviated Drug Labeling, Tariffs, Domestic Manufacturing, DSCSA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2025 · fourth_quarter · Q4
Patent Thickets, Patent Settlements, Interchangeability of biosimilars, Q1Q2 transparency, PBM Reform, Inflation Reduction Act, Abbreviated Drug Labeling, Tariffs, Domestic Manufacturing, DSCSA.
Reimbursement of generic pharmaceuticals and biosimilars.
Country of Origin labeling.
Incentivizing domestic manufacturing of essential medicines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2025 · third_quarter · Q3
Patent Thickets, Patent Settlements, Interchangeability of biosimilars, Q1Q2 transparency, PBM Reform, Inflation Reduction Act, Abbreviated Drug Labeling, Tariffs, Domestic Manufacturing, DSCSA.
Reimbursement of generic pharmaceuticals and biosimilars.
Country of Origin labeling.
Incentivizing domestic manufacturing of essential medicines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2025 · second_quarter · Q2
Patent Thickets, Patent Settlements, Interchangeability of biosimilars, Q1Q2 transparency, PBM Reform, Inflation Reduction Act, Abbreviated Drug Labeling, Tariffs, Domestic Manufacturing, DSCSA.
Reimbursement of generic pharmaceuticals and biosimilars.
Country of Origin labeling.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2025 · first_quarter · Q1
BLOCKING Act, Patent Thickets, Patent Settlements, Interchangeability of biosimilars, Q1Q2 transparency, PBM Reform, Inflation Reduction Act, Abbreviated Drug Labeling, Tariffs, Domestic Manufacturing, DSCSA.
Reimbursement of generic pharmaceuticals and biosimilars.
Country of Origin labeling.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2024 · fourth_quarter · Q4
Issues related to patent thickets, patentability standards and IP influencing applications for drug marketing approval.
Issues related to pharmaceutical pricing and reimbursement.
Issues related to drug innovation and access to medicines.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2024 · third_quarter · Q3
Issues related to finished dose pharmaceutical reimbursement, pricing transparency, and drug disposal.
Issues related to formulary tiering and Medicare rebates.
Issues related to drug innovation and access to medicines.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2024 · second_quarter · Q2
Issues related to addressing drug shortages, including stockpiling and improvements to the drug supply chain.
Issues related to drug innovation and access to medicines.
Issues related to formulary tiering and Medicare rebates.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2024 · first_quarter · Q1
Issues related to finished dose pharmaceutical reimbursement, pricing transparency, and drug disposal.
Issues related to formulary tiering and Medicare rebates.
Issues related to addressing drug shortages, including stockpiling and improvements to the drug supply chain.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2023 · fourth_quarter · Q4
Issues related to pharmaceutical pricing and reimbursement.
Issues related to drug innovation and access to medicines.
Issues related to finished dose pharmaceutical reimbursement, pricing transparency, and drug disposal.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2023 · third_quarter · Q3
Issues related to pharmaceutical pricing and reimbursement.
Issues related to finished dose pharmaceutical reimbursement, pricing transparency, and drug disposal.
Issues related to formulary tiering and Medicare rebates.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2023 · second_quarter · Q2
Lupin Pharmaceuticals Inc. did not lobby on any Disaster Planning/Emergencies legislation this quarter.
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2023 · first_quarter · Q1
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114).
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Lupin Pharmaceuticals Inc. did not lobby on any Disaster Planning/Emergencies legislation this quarter.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2022 · fourth_quarter · Q4
None.
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2022 · third_quarter · Q3
None
None.
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2022 · second_quarter · Q2
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
None.
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping. BLOCKING Act. Medicare drug price negotiations. Drug price inflation rebate penalty in Medicare.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2022 · first_quarter · Q1
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
None.
None
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2021 · fourth_quarter · Q4
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping. BLOCKING Act. Medicare drug price negotiations. Drug price inflation rebate penalty in Medicare.
None
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2021 · third_quarter · Q3
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
None
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2021 · second_quarter · Q2
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2021 · first_quarter · Q1
None.
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2020 · fourth_quarter · 4A
Not applicable this quarter.
New laws governing opioids.
Ensuring the USMCA is framework for US-UK agreement particularly in IP related provisions.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2020 · fourth_quarter · Q4
New laws governing opioids.
Not applicable this quarter.
Ensuring the USMCA is framework for US-UK agreement particularly in IP related provisions.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2020 · third_quarter · Q3
Ensuring the USMCA is framework for US-UK agreement particularly in IP related provisions.
New laws governing opioids.
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2020 · second_quarter · 2A
Not applicable this quarter.
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
New laws governing opioids.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2020 · second_quarter · Q2
BLOCKING Act Patent Settlements CREATES Act CARES Act HEROES Act CARES Act 2.0
New laws governing opioids.
The additional CPI penalty on generic drugs within Medicaid.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2020 · first_quarter · Q1
The additional CPI penalty on generic drugs within Medicaid.
New laws governing opioids.
Ensuring the USMCA is framework for US-UK agreement particularly in IP related provisions.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2019 · fourth_quarter · Q4
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
The additional CPI penalty on generic drugs within Medicaid.
Changes to the USMCA to make agreement consistent with balance in US law in IP related provisions.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2019 · third_quarter · Q3
New laws governing opioids.
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
Lobbying to maintain IPR by PTO. BLOCKING Act FAIR Act (Tina Smith D-MI) TERM Act Patent Settlements CREATES Act
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2019 · second_quarter · Q2
Not applicable this quarter.
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
Changes to the USMCA to make agreement consistent with balance in US law in IP related provisions.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2019 · first_quarter · Q1
Changes to the USMCA to make agreement consistent with balance in US law in IP related provisions.
Not applicable this quarter.
New laws governing opioids.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2018 · fourth_quarter · Q4
USMCA - regarding IP chapter
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2018 · third_quarter · Q3
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2018 · second_quarter · Q2
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2018 · first_quarter · Q1
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
LUPIN PHARMACEUTICALS INC via LUPIN PHARMACEUTICALS INC
2018 · first_quarter · RR
CREATES Act, biosimilars regulation, drug pricing, intellectual property issues related to pharmaceuticals
CREATES Act, biosimilars regulation, drug pricing, intellectual property issues related to pharmaceuticals
CREATES Act, biosimilars regulation, drug pricing, intellectual property issues related to pharmaceuticals
Incentivizing domestic manufacturing of essential medicines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Incentivizing domestic manufacturing of essential medicines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to finished dose pharmaceutical reimbursement, pricing transparency, and drug disposal.
Issues related to addressing drug shortages, including stockpiling and improvements to the drug supply chain.
Issues related to formulary tiering and Medicare rebates.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to patent thickets, patentability standards and IP influencing applications for drug marketing approval.
Issues related to addressing drug shortages, including stockpiling and improvements to the drug supply chain.
Issues related to pharmaceutical pricing and reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmaceutical pricing and reimbursement.
Issues related to finished dose pharmaceutical reimbursement, pricing transparency, and drug disposal.
Issues related to patent thickets, patentability standards and IP influencing applications for drug marketing approval.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to drug innovation and access to medicines.
Issues related to pharmaceutical pricing and reimbursement.
Issues related to patent thickets, patentability standards and IP influencing applications for drug marketing approval.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to addressing drug shortages, including stockpiling and improvements to the drug supply chain.
Issues related to formulary tiering and Medicare rebates.
Issues related to patent thickets, patentability standards and IP influencing applications for drug marketing approval.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to drug innovation and access to medicines.
Issues related to addressing drug shortages, including stockpiling and improvements to the drug supply chain.
Issues related to patent thickets, patentability standards and IP influencing applications for drug marketing approval.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114).
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Lupin Pharmaceuticals Inc. did not lobby on any trade issues this quarter.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Lupin Pharmaceuticals Inc. did not lobby on any trade issues this quarter.
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping. BLOCKING Act. Medicare drug price negotiations. Drug price inflation rebate penalty in Medicare.
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
None
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping. BLOCKING Act. Medicare drug price negotiations. Drug price inflation rebate penalty in Medicare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
None
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping. BLOCKING Act. Medicare drug price negotiations. Drug price inflation rebate penalty in Medicare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
None.
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
None.
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping.
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
None
None.
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
None
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Patent Settlments BLOCKING Act (H.R. 938). Pharmaceutical Supply Chain Medicaid & Medicare
BLOCKING Act Patent Settlements Pharmaceutical Supply chain
Lobbying for AAM's "Blue Print for Enhancing Security of the Supply Chain". No legislation adopts this yet.
The additional CPI penalty on generic drugs within Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
BLOCKING Act Patent Settlements CREATES Act CARES Act HEROES Act CARES Act 2.0
Lobbying for AAM's "Blue Print for Enhancing Security of the Supply Chain". No legislation adopts this yet.
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
The additional CPI penalty on generic drugs within Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
The additional CPI penalty on generic drugs within Medicaid.
Lobbying for AAM's "Blue Print for Enhancing Security of the Supply Chain". No legislation adopts this yet.
Not applicable this quarter.
BLOCKING Act Patent Settlements CREATES Act CARES Act HEROES Act CARES Act 2.0
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Lobbying for AAM's "Blue Print for Enhancing Security of the Supply Chain". No legislation adopts this yet.
The additional CPI penalty on generic drugs within Medicaid.
BLOCKING Act Patent Settlements CREATES Act CARES Act HEROES Act CARES Act 2.0
Ensuring the USMCA is framework for US-UK agreement particularly in IP related provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
Lobbying for AAM's "Blue Print for Enhancing Security of the Supply Chain". No legislation adopts this yet.
Not applicable this quarter.
Ensuring the USMCA is framework for US-UK agreement particularly in IP related provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Not applicable this quarter.
CREATES Act (S. 794). BLOCKING Act (H.R. 938). CARES Act HEROES Act CARES Act 2.0
Lobbying for AAM's "Blue Print for Enhancing Security of the Supply Chain". No legislation adopts this yet.
BLOCKING Act Patent Settlements CREATES Act CARES Act HEROES Act CARES Act 2.0
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
New laws governing opioids.
Lobbying to maintain IPR by PTO. BLOCKING Act FAIR Act (Tina Smith D-MI) TERM Act Patent Settlements CREATES Act
Not applicable this quarter.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
The additional CPI penalty on generic drugs within Medicaid.
Changes to the USMCA to make agreement consistent with balance in US law in IP related provisions.
Not applicable this quarter.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
New laws governing opioids.
The additional CPI penalty on generic drugs within Medicaid.
Lobbying to maintain IPR by PTO.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
CREATES Act (S. 794). BLOCKING Act (H.R. 938). Preserve Access to Affordable Generics Act (S. 64). Hatch-Waxman Integrity Act (S 344).
Lobbying to maintain IPR by PTO.
The additional CPI penalty on generic drugs within Medicaid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. Patent settlements legislation USMCA - regarding IP standards in USMCA. IPR - regarding PTO authority to administrative review of patents.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues.
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. Patent settlements legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CREATES Act, biosimilars regulation, drug pricing, intellectual property issues related to pharmaceuticals